Physician profile
Yu Yao
NPI 1356307821
$2,724.29
in general payments reported to CMS, 2019-2025
23 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $29.77 · 2021: $103 · 2022: $209 · 2023: $77.49 · 2024: $383 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,960.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $503.86 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $361.83 | 2024-2025 | Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.23 | 2025 | Caplyta |
| Abbvie INC. | $266.73 | 2019-2025 | Viberzi, Linzess |
| Amarin Pharma, INC. | $223.07 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.68 | 2019-2025 | Jardiance |
| Agios Pharmaceuticals, INC. | $163.46 | 2024-2025 | Pyrukynd |
| Novo Nordisk INC | $142.16 | 2024-2025 | Ozempic, Rybelsus |
| Acera Surgical, INC. | $120.96 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.94 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Vivus LLC | $47.15 | 2025 | Pancreaze |
| Gilead Sciences, INC. | $40.15 | 2019 | |
| Almatica Pharma LLC | $28.71 | 2025 | Loreev Xr |
| Ardelyx, INC. | $26.53 | 2024 | Ibsrela |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.45 | 2025 | Evenity |
| Abbott Laboratories | $23.10 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $22.79 | 2025 | Cologuard Collection Kit |
| Radius Health, INC. | $19.78 | 2025 | Tymlos |
| Azurity Pharmaceuticals, INC. | $18.62 | 2025 | |
| Lilly USA, LLC | $18.18 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.90 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.80 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.